| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adenine base editor–mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation
|
Hardouin, Giulia
|
|
|
141 |
10 |
p. 1169-1179
|
artikel
|
| 2 |
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
|
Izutsu, Koji
|
|
|
141 |
10 |
p. 1159-1168
|
artikel
|
| 3 |
Back Matter
|
|
|
|
141 |
10 |
p. II
|
artikel
|
| 4 |
2B or not 2B: art thou autoinhibitory?
|
McKinnon, Thomas A. J.
|
|
|
141 |
10 |
p. 1102-1103
|
artikel
|
| 5 |
BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1
|
Delage, Lorric
|
|
|
141 |
10 |
p. 1209-1220
|
artikel
|
| 6 |
Burgos da Silva M, Ponce DM, Dai A, et al. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease. Blood. 2022;140(22):2385-2397.
|
|
|
|
141 |
10 |
p. 1234
|
artikel
|
| 7 |
CD53 sends HSCs to sweet DREAMs
|
Karabacz, Noémie
|
|
|
141 |
10 |
p. 1100-1101
|
artikel
|
| 8 |
Daher M, Basar R, Gokdemir E, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624-636.
|
|
|
|
141 |
10 |
p. 1235
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
141 |
10 |
p. x
|
artikel
|
| 10 |
Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation
|
Mo, Feiyan
|
|
|
141 |
10 |
p. 1194-1208
|
artikel
|
| 11 |
Harnessing ADR T cells to enhance allo-HCT
|
Smith, Melody
|
|
|
141 |
10 |
p. 1101-1102
|
artikel
|
| 12 |
How I diagnose and treat acute graft-versus-host disease after solid organ transplantation
|
Cooper, Jason P.
|
|
|
141 |
10 |
p. 1136-1146
|
artikel
|
| 13 |
It is more “unbalanced” than you think
|
Malinge, Sébastien
|
|
|
141 |
10 |
p. 1095-1096
|
artikel
|
| 14 |
Masthead Subscription
|
|
|
|
141 |
10 |
p. i
|
artikel
|
| 15 |
Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets
|
Mishra, Sushanta Kumar
|
|
|
141 |
10 |
p. 1119-1135
|
artikel
|
| 16 |
Peripheral erythrophagocytosis in paroxysmal cold hemoglobinuria
|
Matson, Daniel R.
|
|
|
141 |
10 |
p. 1233
|
artikel
|
| 17 |
Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757.
|
|
|
|
141 |
10 |
p. 1234
|
artikel
|
| 18 |
RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia
|
Gialesaki, Sofia
|
|
|
141 |
10 |
p. 1105-1118
|
artikel
|
| 19 |
Semple JW, Kapur R. Protecting the fetus from FNAIT. Blood. 2022;140(20):2097-2099.
|
|
|
|
141 |
10 |
p. 1235
|
artikel
|
| 20 |
Synthetic lethality in ATL
|
Chihara, Dai
|
|
|
141 |
10 |
p. 1096-1098
|
artikel
|
| 21 |
Table of Contents
|
|
|
|
141 |
10 |
p. iii-v
|
artikel
|
| 22 |
β-Thalassemia: all about that base, no cutting
|
Ayoub, Paul G.
|
|
|
141 |
10 |
p. 1098-1099
|
artikel
|
| 23 |
The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex–mediated quiescence
|
Greenberg, Zev J.
|
|
|
141 |
10 |
p. 1180-1193
|
artikel
|
| 24 |
The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
|
Ay, Cihan
|
|
|
141 |
10 |
p. 1147-1158
|
artikel
|
| 25 |
Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain
|
Legan, Emily R.
|
|
|
141 |
10 |
p. 1221-1232
|
artikel
|
Tijdschrift beschrijving